← Back to Search

Depemokimab for Hypereosinophilic Syndrome (DESTINY Trial)

Phase 3
Recruiting
Research Sponsored by GlaxoSmithKline
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
A history of 2 or more HES flares within the past 12 months prior to Visit 1
Participants who are greater than or equal (>=) 40 kilogram (kg) at Screening Visit 1
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 52 weeks
Awards & highlights

DESTINY Trial Summary

This trialwill test a drug to control HES flare-ups in adults with uncontrolled HES who are already on standard therapy.

Who is the study for?
Adults with Hypereosinophilic Syndrome (HES) who are not pregnant or breastfeeding, weigh at least 40 kg, have had a confirmed HES diagnosis and experienced two or more flares in the past year can join. They must be on stable HES therapy for four weeks before the trial and cannot have certain cancers, heart issues, severe allergies to monoclonal antibodies, or other specific health conditions.Check my eligibility
What is being tested?
The study is testing Depemokimab against a placebo in people with uncontrolled HES over one year. Participants will continue their standard care while being randomly assigned to either receive Depemokimab or a placebo in a 2:1 ratio.See study design
What are the potential side effects?
Potential side effects of Depemokimab may include reactions similar to those seen with other monoclonal antibody treatments such as infusion-related reactions, immune system changes leading to inflammation of organs, fatigue, allergic responses and possibly an increased risk of infections.

DESTINY Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have had 2 or more episodes of severe allergic reactions in the last year.
Select...
I weigh at least 40 kg.
Select...
I have been diagnosed with HES before my second visit.

DESTINY Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 52 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 52 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Frequency of HES flares
Secondary outcome measures
Change from Baseline to Week 52 in weekly average score of Brief Fatigue Inventory (BFI) item 3 (worst fatigue in last 24 hours)
Number of participants with at least one HES flare during the 52-week study intervention period
Time to first HES flare

DESTINY Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: DepemokimabExperimental Treatment1 Intervention
All participants in this arm will receive depemokimab.
Group II: PlaceboPlacebo Group1 Intervention
All participants in this arm will receive placebo.

Find a Location

Who is running the clinical trial?

GlaxoSmithKlineLead Sponsor
4,753 Previous Clinical Trials
8,069,338 Total Patients Enrolled
7 Trials studying Hypereosinophilic Syndrome
409 Patients Enrolled for Hypereosinophilic Syndrome
GSK Clinical TrialsStudy DirectorGlaxoSmithKline
3,595 Previous Clinical Trials
6,143,810 Total Patients Enrolled
6 Trials studying Hypereosinophilic Syndrome
399 Patients Enrolled for Hypereosinophilic Syndrome

Media Library

Depemokimab Clinical Trial Eligibility Overview. Trial Name: NCT05334368 — Phase 3
Hypereosinophilic Syndrome Research Study Groups: Placebo, Depemokimab
Hypereosinophilic Syndrome Clinical Trial 2023: Depemokimab Highlights & Side Effects. Trial Name: NCT05334368 — Phase 3
Depemokimab 2023 Treatment Timeline for Medical Study. Trial Name: NCT05334368 — Phase 3

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

When might we see Depemokimab available for general use?

"Depemokimab has received a score of 3 for safety from our team at Power. This is because Depemokimab is in Phase 3 trials, which means that there is some data to support both efficacy and safety."

Answered by AI

Are there opportunities for new participants in this experiment?

"The clinical trial is recruiting participants and was first posted on September 6, 2022. The most recent update was on October 31, 2022."

Answered by AI
~64 spots leftby Feb 2026